These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28146363)

  • 1. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia].
    Maychuk DY; Yani EV; Brzheskiy VV; Grishina EE; Drozdova EA; Maychuk NV; Panova IE; Safonova TN
    Vestn Oftalmol; 2024; 140(2):102-111. PubMed ID: 38742506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
    Boboridis KG; Konstas AGP
    Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
    Levy O; Labbé A; Borderie V; Laroche L; Bouheraoua N
    J Fr Ophtalmol; 2016 Mar; 39(3):292-307. PubMed ID: 26997607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
    Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease.
    Hind J; Macdonald E; Lockington D
    Eye (Lond); 2019 Apr; 33(4):685-686. PubMed ID: 30498263
    [No Abstract]   [Full Text] [Related]  

  • 17. A Novel Eyes Topical Drug Delivery System: CsA-LNC for the Treatment of DED.
    Zhang A; Sun R; Ran M; Deng Y; Ge Y; Zhu Y; Tao X; Shang L; Gou J; He H; Yin T; Wang Y; Zhang Y; Tang X
    Pharm Res; 2020 Jul; 37(7):146. PubMed ID: 32666340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
    Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
    Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
    Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
    Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
    Ji YW; Kim HM; Ryu SY; Oh JW; Yeo A; Choi CY; Kim MJ; Song JS; Kim HS; Seo KY; Kim KP; Lee HK
    Invest Ophthalmol Vis Sci; 2019 Dec; 60(15):5035-5044. PubMed ID: 31800960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.